The case for therapeutic proteostasis modulators

Neeraj Vij

Research output: Contribution to journalArticle

Abstract

A functional ubiquitin proteasome pathway (UPP) is vital for all eukaryotic cellular systems and therefore any alteration in this critical component of proteostasis machinery has rpotential pathological consequences. A proteostasis imbalance can be induced by environmental pollutants, age or genetic factors. Though the exact underlying mechanisms are unclear, a decrease in proteasome activity weakens the homeostatic cellular capacity to remove proteins that are either misfolded or need to be replenished, which favors the development of neurodegenerative, cardiac and other conformational diseases. In contrast, induction of proteasome activity is an attribute of many diseases including muscle wasting, sepsis, cachexia and uraemia. In the case of misfolded protein disorders, higher degradation of a single protein leads to the pathophysiological consequences due to the absence of functional protein. Therefore, selective proteostasis inhibition is a potential treatment strategy for misfolded protein disorders, while broad-spectrum proteasome inhibitor drugs are designed to target tumor metastasis. In contrast, for muscle wasting and neurodegeneration, the use of proteostasis-activating or modulating compounds could be more effective.

Original languageEnglish (US)
Pages (from-to)233-236
Number of pages4
JournalExpert Opinion on Therapeutic Targets
Volume15
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Proteasome Endopeptidase Complex
Proteostasis Deficiencies
Modulators
Disease Attributes
Muscles
Environmental Pollutants
Cachexia
Proteins
Proteasome Inhibitors
Uremia
Muscle
Ubiquitin
Sepsis
Therapeutics
Neoplasm Metastasis
Machinery
Tumors
Pharmaceutical Preparations
Neoplasms
Degradation

Keywords

  • Degradation
  • Proteasome
  • Proteostasis
  • Therapeutics
  • Ubiquitin

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

The case for therapeutic proteostasis modulators. / Vij, Neeraj.

In: Expert Opinion on Therapeutic Targets, Vol. 15, No. 3, 03.2011, p. 233-236.

Research output: Contribution to journalArticle

Vij, Neeraj. / The case for therapeutic proteostasis modulators. In: Expert Opinion on Therapeutic Targets. 2011 ; Vol. 15, No. 3. pp. 233-236.
@article{67f102e6419141d6a2153dd731b87a13,
title = "The case for therapeutic proteostasis modulators",
abstract = "A functional ubiquitin proteasome pathway (UPP) is vital for all eukaryotic cellular systems and therefore any alteration in this critical component of proteostasis machinery has rpotential pathological consequences. A proteostasis imbalance can be induced by environmental pollutants, age or genetic factors. Though the exact underlying mechanisms are unclear, a decrease in proteasome activity weakens the homeostatic cellular capacity to remove proteins that are either misfolded or need to be replenished, which favors the development of neurodegenerative, cardiac and other conformational diseases. In contrast, induction of proteasome activity is an attribute of many diseases including muscle wasting, sepsis, cachexia and uraemia. In the case of misfolded protein disorders, higher degradation of a single protein leads to the pathophysiological consequences due to the absence of functional protein. Therefore, selective proteostasis inhibition is a potential treatment strategy for misfolded protein disorders, while broad-spectrum proteasome inhibitor drugs are designed to target tumor metastasis. In contrast, for muscle wasting and neurodegeneration, the use of proteostasis-activating or modulating compounds could be more effective.",
keywords = "Degradation, Proteasome, Proteostasis, Therapeutics, Ubiquitin",
author = "Neeraj Vij",
year = "2011",
month = "3",
doi = "10.1517/14728222.2011.553610",
language = "English (US)",
volume = "15",
pages = "233--236",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - The case for therapeutic proteostasis modulators

AU - Vij, Neeraj

PY - 2011/3

Y1 - 2011/3

N2 - A functional ubiquitin proteasome pathway (UPP) is vital for all eukaryotic cellular systems and therefore any alteration in this critical component of proteostasis machinery has rpotential pathological consequences. A proteostasis imbalance can be induced by environmental pollutants, age or genetic factors. Though the exact underlying mechanisms are unclear, a decrease in proteasome activity weakens the homeostatic cellular capacity to remove proteins that are either misfolded or need to be replenished, which favors the development of neurodegenerative, cardiac and other conformational diseases. In contrast, induction of proteasome activity is an attribute of many diseases including muscle wasting, sepsis, cachexia and uraemia. In the case of misfolded protein disorders, higher degradation of a single protein leads to the pathophysiological consequences due to the absence of functional protein. Therefore, selective proteostasis inhibition is a potential treatment strategy for misfolded protein disorders, while broad-spectrum proteasome inhibitor drugs are designed to target tumor metastasis. In contrast, for muscle wasting and neurodegeneration, the use of proteostasis-activating or modulating compounds could be more effective.

AB - A functional ubiquitin proteasome pathway (UPP) is vital for all eukaryotic cellular systems and therefore any alteration in this critical component of proteostasis machinery has rpotential pathological consequences. A proteostasis imbalance can be induced by environmental pollutants, age or genetic factors. Though the exact underlying mechanisms are unclear, a decrease in proteasome activity weakens the homeostatic cellular capacity to remove proteins that are either misfolded or need to be replenished, which favors the development of neurodegenerative, cardiac and other conformational diseases. In contrast, induction of proteasome activity is an attribute of many diseases including muscle wasting, sepsis, cachexia and uraemia. In the case of misfolded protein disorders, higher degradation of a single protein leads to the pathophysiological consequences due to the absence of functional protein. Therefore, selective proteostasis inhibition is a potential treatment strategy for misfolded protein disorders, while broad-spectrum proteasome inhibitor drugs are designed to target tumor metastasis. In contrast, for muscle wasting and neurodegeneration, the use of proteostasis-activating or modulating compounds could be more effective.

KW - Degradation

KW - Proteasome

KW - Proteostasis

KW - Therapeutics

KW - Ubiquitin

UR - http://www.scopus.com/inward/record.url?scp=79951630982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951630982&partnerID=8YFLogxK

U2 - 10.1517/14728222.2011.553610

DO - 10.1517/14728222.2011.553610

M3 - Article

C2 - 21250874

AN - SCOPUS:79951630982

VL - 15

SP - 233

EP - 236

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 3

ER -